Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers
Study Overview
Purpose: FGFR2b protein overexpression is an important biomarker in gastric cancer. This study evaluated how common FGFR2b overexpression is in nearly 3,800 tumor samples from patients with advanced or metastatic gastric cancer (GC) during the prescreening for the Phase III FORTITUDE-101 trial.
Methods:
As of June 28, 2024, a total of 3,782 tumor samples from 37 countries were analyzed for FGFR2b overexpression using immunohistochemistry (IHC). We defined FGFR2b positivity as tumor cells showing moderate-to-strong FGFR2b staining in any percentage, with ≥10% of tumor cells also meeting this criterion.
Results:
Key Findings:
- 37.8% of patients (1,428 out of 3,782) showed FGFR2b protein overexpression at any level.
- 16.2% of patients (612 out of 3,782) exhibited FGFR2b overexpression in ≥10% of tumor cells.
- Among the positive tumors, 42.9% had FGFR2b levels ≥10%.
FGFR2b overexpression rates were consistent across various patient characteristics, such as age, sex, and geographical location.
Conclusion:
This study presents the largest assessment of FGFR2b protein overexpression in gastric cancer, revealing that over one-third of patients have this biomarker present. Understanding FGFR2b prevalence can help in developing targeted treatments for gastric cancer patients.
Value of Clinical Trials
Clinical trials are essential for creating safe and effective treatments. Our AI-driven platform, DocSym, combines ICD-11 standards, clinical protocols, and research into one accessible resource for healthcare providers.
Streamlining Healthcare
In today’s medical environment, efficiency is vital. Our mobile applications assist with scheduling, monitoring treatments, and telemedicine, facilitating better patient management and digital service expansion.
By leveraging AI, clinics can optimize their workflows, enhance patient outcomes, and reduce paperwork. Discover more about our solutions at aidevmd.com.
